Aurinia Pharmaceuticals Inc (IKAP F) stock market data APIs
€12.7653
-0.07(-0.5%)
as of January 16, 2026
Try our APIs with
free plan!
Aurinia Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Prev. Close
12.7653
Open
12.6969
High
12.8211
Low
12.6547
52 wk Range
6.19-14.27
Market Cap
1 685 M
P/E Ratio
26.5104
Shares Outstanding
132 M
Revenue
266 M
EPS
-0.37
Beta
1.474
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aurinia Pharmaceuticals Inc data using free add-ons & libraries
Get Aurinia Pharmaceuticals Inc Fundamental Data
Aurinia Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 266 M
- EBITDA: 101 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-05
- EPS/Forecast: -0.36
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aurinia Pharmaceuticals Inc News
New
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million Preliminary unaudited net product revenue for the fourth quarter and fu...
Painful week for retail investors invested in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) after 5.9% drop, institutions also suffered losses
Key Insights Significant control over Aurinia Pharmaceuticals by retail investors implies that the general public has more power to influence management and governance-related decisions The top 25 sh...
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Aurinia Pharmaceuticals (AUPH) is a stock that can certainly grab...
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) Upon FDA...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
